Literature DB >> 35187960

Role of the arterial baroreflex in the sympathetic response to hyperinsulinemia in adult humans.

Neil J McMillan1, Rogerio N Soares2, Jennifer L Harper1, Brian Shariffi1, Alfonso Moreno-Cabañas1,3, Timothy B Curry4, Camila Manrique-Acevedo2,5,6, Jaume Padilla1,2, Jacqueline K Limberg1,4,2.   

Abstract

Muscle sympathetic nerve activity (MSNA) increases during hyperinsulinemia, primarily attributed to central nervous system effects. Whether peripheral vasodilation induced by insulin further contributes to increased MSNA via arterial baroreflex-mediated mechanisms requires further investigation. Accordingly, we examined baroreflex modulation of the MSNA response to hyperinsulinemia. We hypothesized that rescuing peripheral resistance with coinfusion of the vasoconstrictor phenylephrine would attenuate the MSNA response to hyperinsulinemia. We further hypothesized that the insulin-mediated increase in MSNA would be recapitulated with another vasodilator (sodium nitroprusside, SNP). In 33 young healthy adults (28 M/5F), MSNA (microneurography) and arterial blood pressure (BP, Finometer/brachial catheter) were measured, and total peripheral resistance (TPR, ModelFlow) and baroreflex sensitivity were calculated at rest and during intravenous infusion of insulin (n = 20) or SNP (n = 13). A subset of participants receiving insulin (n = 7) was coinfused with phenylephrine. Insulin infusion decreased TPR (P = 0.01) and increased MSNA (P < 0.01), with no effect on arterial baroreflex sensitivity or BP (P > 0.05). Coinfusion with phenylephrine returned TPR and MSNA to baseline, with no effect on arterial baroreflex sensitivity (P > 0.05). Similar to insulin, SNP decreased TPR (P < 0.02) and increased MSNA (P < 0.01), with no effect on arterial baroreflex sensitivity (P > 0.12). Acute hyperinsulinemia shifts the baroreflex stimulus-response curve to higher MSNA without changing sensitivity, likely due to insulin's peripheral vasodilatory effects. Results show that peripheral vasodilation induced by insulin contributes to increased MSNA during hyperinsulinemia.NEW & NOTEWORTHY We hypothesized that elevation in muscle sympathetic nervous system activity (MSNA) during hyperinsulinemia is mediated by its peripheral vasodilator effect on the arterial baroreflex. Using three separate protocols in humans, we observed increases in both MSNA and cardiac output during hyperinsulinemia, which we attributed to the baroreflex response to peripheral vasodilation induced by insulin. Results show that peripheral vasodilation induced by insulin contributes to increased MSNA during hyperinsulinemia.

Entities:  

Keywords:  autonomic nervous system; baroreflex sensitivity; blood pressure; insulin; peripheral resistance

Mesh:

Substances:

Year:  2022        PMID: 35187960      PMCID: PMC8993537          DOI: 10.1152/ajpendo.00391.2021

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  67 in total

1.  Skeletal muscle microvascular insulin resistance in type 2 diabetes is not improved by eight weeks of regular walking.

Authors:  Lauren K Park; Elizabeth J Parks; Ryan J Pettit-Mee; Makenzie L Woodford; Thaysa Ghiarone; James A Smith; Allan R K Sales; Luis A Martinez-Lemus; Camila Manrique-Acevedo; Jaume Padilla
Journal:  J Appl Physiol (1985)       Date:  2020-07-02

2.  Sympathetic baroreflex sensitivity is inversely related to vascular transduction in men but not women.

Authors:  Sarah L Hissen; Vaughan G Macefield; Rachael Brown; Chloe E Taylor
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-11-01       Impact factor: 4.733

3.  Abnormal sympathetic overactivity evoked by insulin in the skeletal muscle of patients with essential hypertension.

Authors:  G Lembo; R Napoli; B Capaldo; V Rendina; G Iaccarino; M Volpe; B Trimarco; L Saccà
Journal:  J Clin Invest       Date:  1992-07       Impact factor: 14.808

4.  Effect of exogenous nitric oxide on baroreflex function in humans.

Authors:  N Hogan; A Kardos; D J Paterson; B Casadei
Journal:  Am J Physiol       Date:  1999-07

5.  Transport of insulin across the blood-brain barrier: saturability at euglycemic doses of insulin.

Authors:  W A Banks; J B Jaspan; W Huang; A J Kastin
Journal:  Peptides       Date:  1997       Impact factor: 3.750

6.  Insulin in the brain increases gain of baroreflex control of heart rate and lumbar sympathetic nerve activity.

Authors:  Mollie P Pricher; Korrina L Freeman; Virginia L Brooks
Journal:  Hypertension       Date:  2007-12-24       Impact factor: 10.190

7.  Impaired insulin-induced sympathetic neural activation and vasodilation in skeletal muscle in obese humans.

Authors:  P Vollenweider; D Randin; L Tappy; E Jéquier; P Nicod; U Scherrer
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

8.  Rapid resetting of human baroreflex working range: insights from sympathetic recordings during acute hypoglycaemia.

Authors:  J Fagius; C Berne
Journal:  J Physiol       Date:  1991-10       Impact factor: 5.182

Review 9.  Assessment of resistance vessel function in human skeletal muscle: guidelines for experimental design, Doppler ultrasound, and pharmacology.

Authors:  Jacqueline K Limberg; Darren P Casey; Joel D Trinity; Wayne T Nicholson; D Walter Wray; Michael E Tschakovsky; Daniel J Green; Ylva Hellsten; Paul J Fadel; Michael J Joyner; Jaume Padilla
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-12-30       Impact factor: 4.733

10.  Insulin-induced sympathetic activation and vasodilation in skeletal muscle. Effects of insulin resistance in lean subjects.

Authors:  L Vollenweider; L Tappy; R Owlya; E Jéquier; P Nicod; U Scherrer
Journal:  Diabetes       Date:  1995-06       Impact factor: 9.461

View more
  1 in total

Review 1.  Role of the Autonomic Nervous System in the Hemodynamic Response to Hyperinsulinemia-Implications for Obesity and Insulin Resistance.

Authors:  Jacqueline K Limberg; Rogerio N Soares; Jaume Padilla
Journal:  Curr Diab Rep       Date:  2022-03-05       Impact factor: 4.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.